Ataxias hereditarias y COVID-19: posibles implicaciones fisiopatológicas y recomendaciones
Resumen
Palabras clave
Referencias
Johns Hopkins University. Coronavirus COVID-19 Global cases by the Center for Systems Sciences and Engineering. (2020) Recuperado el 18 de abril de 2020. Disponible en: https://coronavirus.jhu.edu/map.html
Yang J, Zheng Y, Ggou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2020 S1201-9712(20)30136-3. DOI: https://doi.org/10.1016/j.ijid.2020.03.017 Reference: IJID 4023
Mao L, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. JAMA Neurol. 2020. DOI:10.1001/jamaneurol.2020.1127
Helm et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med??. 2020. DOI: 10.1056/NEJMc2008597
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020. DOI: 10.1002/jmv.25728. [Epub ahead of print] Review.
Leon Castellon R, Bender del Busto JE, Velazquez-Pérez L. Afectación del sistema nervioso por la COVID-19. Anales de la Academia de Ciencias de Cuba. 2020; 10(2). Disponible en: http://www.revistaccuba.sld.cu/index.php/revacc/article/view/760
Polkey ML, Lyall RA, Moxham J, Leigh PN. Respiratory aspects of neurological disease. J Neurol Neurosurg Psychiatry 1999;66:5-15.
Netland J, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82:7264-7275.
Stadler K, et al. SARS-beginning to understand a new virus. Nature Rev. Microbiol. 2003;1:209-218.
Phan T. Genetic diversity and evolution of SARS-CoV2. Inf Gen Evol. 2020; 81:104260.
Velazquez-Pérez L, et al., (2020). Hereditary Ataxias in Cuba: A Nationwide Epidemiological and Clinical Study in 1001 Patients. Cerebellum. In press. https://doi.org/10.1007/s12311-020-01107-9
Hersheson J, Haworth A, Houlden H. The inherited ataxias: genetic heterogeneity, mutation databases, and future directions in research and clinical diagnostics. Hum Mutat. 2012; 33(9):1324-32.
Evert BO, Vogt IR, Kindermann C et al. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains. Journal of Neuroscience. 2001; 21(15): 5389-5396.
Evert BO, Vogt IR, Vieira-Saecker AM. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. Journal of Neuropathology and Experimental Neurology. 2003; 62(10): 1006-1018.
Raposo M, Bettencourt C, Ramos A. Promoter Variation and Expression Levels of Inflammatory GenesIL1A, IL1B, IL6andTNFin Blood of Spinocerebellar Ataxia Type 3 (SCA3) Patients. Neuromolecular Med. 2017; 19(1):41-45.
Björkqvist M, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington disease. J. Exp. Med. 2008; 205(8): 1869-1877.
Gordo Goméz YM, RamÃrez Guerra DM, RodrÃguez Labrada R, Velázquez Pérez LC. Alteraciones respiratorias de la ataxia espinocerebelosa tipo 2: de las bases fisiopatológicas a su impacto en la neurorrehabilitación. CCM 2018; (4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1560-43812018000100010
Sriranjini SJ, Pal PK, Krishna N, Sathyaprabha TN. Subclinical pulmonary dysfunction in spinocerebellar ataxias 1, 2 and 3. Acta Neurol Scand. 2010[citado 18 ene 2018]; 122(5):323-328
Velázquez Pérez L, Voss U, RodrÃguez Labrada R, Auburger G, Canales Ochoa N, Sánchez Cruz G, et al. Sleep Disorders in Spinocerebellar Ataxia Type 2 Patients. Neurodegener Dis. 2011 [citado 18 ene 2017]; 8(6):447-454.
Gierga K, Bürk K, Bauer M, Orozco Diaz G, Auburger G, Schultz C,et al. Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2). Acta Neuropathol. 2005[citado 18 ene 2017];109(6):617-631.
Auburger G, Sen NE, Meierhofer D, Basak AN, Gitler AD. Efficient Prevention of Neurodegenerative Diseases by Depletion of Starvation Response Factor Ataxin-2. Trends Neurosci (2017). http://dx.doi.org/10.1016/j.tins.2017.06.004.
Ostrowski LA, Hall AC, Mekhail K. Ataxin-2: From RNA Control to Human Health and Disease. Genes. 2017; 8:157; doi:10.3390/genes8060157.
Pandolfo M. Friedreich ataxia: The clinical picture. J Neurol. 2009; 256(1): 3-8.
Begin R, Lupien L, Bureau MA et al. Regulation of respiration in Friedreich`s ataxia. Can J Neurol Sci. 1979; 2:159-65.
Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004;3:1187-96.
Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831-6.
Shaikh AG, Mitoma H, Manto M. Cerebellar Scholars’ Challenging Time in COVID-19 Pandemia. Cerebellum. 2020. https://doi.org/10.1007/s12311-020-01131-9.
Stoessl AJ, Bhatia KP, Merello M. Movement Disorders in the World of COVID-19. Mov Disord. 2020. doi:10.1002/mds.28069
Papa SM, Brundin P, Fung VS, Kang UJ, Burn DJ, Colosimo C, Chiang HL, Alcalay RN, Trenkwalder C. Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. Mov Disord. 2020. doi:10.1002/mds.28067
Jiang, H., Tang, B. Expert consensus on the management strategy of patients with hereditary ataxia during prevention and control of novel coronavirus pneumonia epidemic. Zhonghua Yixue Yichuanxue Zazhi, Chinese Journal of Medical Genetics. 2020;37(4): 359-366. PMID: 32219814.

Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.